Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$7.1B
347M shares
52-week range
$15.29 – $20.90
95% from low
Sector
REAL ESTATE INVESTMENT TRUSTS
Exchange
NYSE
CS
Borrow rate
0.33%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $695.3M | $693.6M | $735.1M | $534.8M | $932.6M | $1.34B | $1.27B | $1.18B |
| Cost of revenue | $778.7M | $890.5M | $925.2M | $617.7M | $1.25B | $1.96B | $1.82B | $1.58B |
| Gross profit | −$83.5M | −$196.8M | −$190.2M | −$82.9M | −$317.6M | −$618.1M | −$555.4M | −$396.5M |
| Gross margin | -12.0% | -28.4% | -25.9% | -15.5% | -34.1% | -46.0% | -43.8% | -33.6% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $160.0M | $49.8M | $69.7M | $85.7M | $78.7M | $49.8M | $36.4M | $94.9M |
| EBITDA | $598.8M | $321.1M | $357.3M | $321.9M | $635.7M | $717.3M | $266.6M | $520.0M |
| Net income | $213.5M | $30.2M | $52.6M | $66.7M | $40.9M | −$278.3M | −$654.5M | −$246.1M |
| Net margin | 30.7% | 4.3% | 7.2% | 12.5% | 4.4% | -20.7% | -51.6% | -20.8% |
| EPS (diluted) | 1.02 | 0.14 | 0.24 | 0.45 | 0.15 | -0.74 | -1.81 | -0.71 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.1B | $-0.02 | $-0.02–$-0.02 | 3 |
| 2027 | $1.2B | $0.02 | $0.02–$0.03 | 2 |
| 2028 | $1.2B | $0.09 | $0.05–$0.13 | 2 |
| 2029 | $1.2B | $0.11 | $0.11–$0.11 | 1 |
Forward consensus · source: Financial Modeling Prep
Healthcare Realty Trust Inc is a healthcare facility real estate investment trust. The company focuses on owning, leasing, and managing outpatient facilities and other healthcare properties. The company works to invest in outpatient facilities that are integral to a hospital's operations. It generates all of its revenue in the United States.
www.healthcarerealty.comNo one on the platform currently holds HR.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,549,172 | $26.3M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-11 | $0.2400 | 2026-05-22 |
| 2026-02-24 | $0.2400 | 2026-03-11 |
| 2025-11-10 | $0.2400 | 2025-11-21 |
| 2025-08-14 | $0.2400 | 2025-08-28 |
| 2025-05-12 | $0.3100 | 2025-05-23 |
| 2025-03-03 | $0.3100 | 2025-03-19 |
| 2024-11-12 | $0.3100 | 2024-11-27 |
| 2024-08-12 | $0.3100 | 2024-08-28 |
| 2024-05-10 | $0.3100 | 2024-05-23 |
| 2024-02-23 | $0.3100 | 2024-03-14 |
No one on the platform has traded HR yet.
| -0.33% |
| $8.4B |
| — |
| OPENOpendoor Technologies Inc. | $4.60 | +5.26% | $3.5B | — |
| RITMRithm Capital Corp. | $9.42 | +0.43% | $5.3B | — |
Source: Financial Modeling Prep · peers by sector/industry
| 2023-11-13 |
| $0.3100 |
| 2023-11-30 |
| 2023-08-14 | $0.3100 | 2023-08-30 |
| Execution date | Ratio |
|---|---|
| 2014-12-16 | 1-for-2reverse |
Trading at 6.2× sales vs its 5.1× historical median P/S.
Fair value ≈ $17.00 · price $20.64 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$HR Share Price: $20.52 Contract Selected: Nov 20, 2026 $20 Calls Buy Zone: $0.89 – $1.10 Target Zone: $1.60 – $1.96 Potential Upside: 69% ROI Time to Expiration: 156 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗Remember this past Sunday at ASCO? The entire auditorium erupted into a standing ovation for $RVMD. Their "homerun" hazard ratio printed at **0.40**, completely doubling pancreatic cancer survival to 13.2mo vs 6.6mo. It was history in the making. 🚀 Now look at $SLS, the FDA approval bar for their Phase 3 REGAL trial is an $HR of 0.636. soo if Best Available Therapy (BAT) holds at the historical 8.0 months: **The "Good" Win:** GPS hits **12.6 months** HR = 0.636 rock-solid FDA approval. **THE GRAND SLAM:** If GPS hits the **20 to 24-month mark** (just like it did in Phase 2), the HR plummets **0.33 to 0.40 range** matches or beats the $RVMD bar, flips the AML world on its f*ckin head, and SLS$ goes to the moon. 🌌 $RVMD sits at $33.6B $SLS now has 196.6M shares outstanding—making its share structure incredibly close to $RVMD. If we print a grand slam 0.40s and hit full valuation parity with $RVMD, $SLS doesn't just hit $25 or $50... mathematically, we fly straight to $171.00
View on StockTwits ↗$HR Large-cap companies maintain robust capital market access for debt refinancing and equity raises, while small-cap and emerging companies face elevated borrowing costs, equity dilution, and reliance on specialized lenders. Learn more: https://axlfi.com/themes/289
View on StockTwits ↗$HR Large-cap companies maintain robust capital market access for debt refinancing and equity raises, while small-cap and emerging companies face elevated borrowing costs, equity dilution, and reliance on specialized lenders. Learn more: https://axlfi.com/themes/289
View on StockTwits ↗$HR Current Stock Price: $19.86 Contracts to trade: $20.0 HR May 15 2026 Call Entry: $0.32 Exit: $0.59 ROI: 87% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$HR Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.00 • Reported revenue of $275.28M down -6.76% YoY • Healthcare Realty increased its 2026 Normalized FFO guidance range to $1.59 to $1.65 per share (diluted) and raised its Same Store Cash NOI growth guidance range to 3.75% to 4.75%.
View on StockTwits ↗$HR awesomeness, fundamentals on point 🖍️💪 $UNH where you at ?? 🏅
View on StockTwits ↗$SLS REGAL P3: The Math Predicts a Historic HR Breakdown 🔬The Survivor Gap: 126 enrolled, only 72/80 events by Dec '25 = 54 survivors (43%). It's been 23 months since full recruitment (Apr '24).The Logic: CR2 AML control mOS is <10 months. If the control group followed history, >85% would have reached an "event" by month 20. The 43% survival rate proves GPS is carrying the curve.HR Forecast: Using $HR \approx mOS_{Control} / mOS_{GPS}$. With Control at 10 and GPS likely 25+ months (due to increased Phase 3 dosing frequency), HR will crash below 0.45, likely hitting 0.35–0.40.ShutterstockIntegrity: IDMC oversight + 6-year trial duration. If GPS didn't work, 80 events would have been reached years ago. The "delay" is actually the proof of efficacy.Verdict: Potential HR of 0.35-0.45. This isn't just a pass; it’s a clinical home run.#SLS #AML #Biotech #FDA #GPS #StockMarket
View on StockTwits ↗$HR Share Price: $18.62 Contract Selected: Aug 21, 2026 $20 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.61 – $0.74 Potential Upside: 50% ROI Time to Expiration: 175 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$HR hypothetical I want this at $50 , and then some oscillation Im going to read into technicals 🥶🤖🧍🏼♂️
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.